Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T20:47:08.277Z.
Calculation as of: 2026-10-06T20:47:08.277Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 610e9c20fcdf10729c15ba1bd616707a7081826ce2aba31979c935d5001cdfd8
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$1.40B
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.39B
Price/FCF Ratio
53.45
TTM Avg
40.41
3Y Avg
45.21
5Y Avg
44.82
Market Cap
$1.42B
Price/FCF Ratio
78.62
TTM Avg
258.29
3Y Avg
258.29
5Y Avg
172.61
Market Cap
$1.42B
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.45B
Price/FCF Ratio
9.57
TTM Avg
9.98
3Y Avg
22.18
5Y Avg
99.17
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | $1.40B | N/A | N/A | N/A | N/A |
| Taysha Gene Therapies, Inc. (TSHA)vs › | $1.40B | N/A | N/A | N/A | N/A |
| Braveheart Bio, Inc. (BRVE)vs › | $1.40B | N/A | N/A | N/A | N/A |
| The Pennant Group, Inc. (PNTG)vs › | $1.39B | 53.45 | 40.41 | 45.21 | 44.82 |
| AnaptysBio, Inc. (ANAB)vs › | $1.42B | 78.62 | 258.29 | 258.29 | 172.61 |
| Ultragenyx Pharmaceutical Inc. (RARE)vs › | $1.42B | N/A | N/A | N/A | N/A |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.37B | N/A | N/A | N/A | N/A |
| Certara, Inc. (CERT)vs › | $1.44B | 23.40 | 16.96 | 29.77 | 40.80 |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.45B | 9.57 | 9.98 | 22.18 | 99.17 |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.46B | N/A | 7.24 | 7.24 | 7.24 |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
